�鶹Ů��

What we don’t yet know about GLP-1s — and why it’s important to find out. (Leana S. Wen, 11/13)

The long era of sitting quietly while the doctor pronounces what ails us and what to do about it is ending. (Cory Franklin, 11/14)

For decades, the pharmaceutical industry’s approach to mental health was a playbook of conservative, incremental innovation. The market was saturated with me-too drugs — slight variations on existing antidepressants and antipsychotics that offered predictable, modest returns. For investors, it was a safe bet. For patients suffering from the most severe forms of mental illness, it was a story of stagnation. (Khutaija Noor, 11/14)

The road map to fighting Alzheimer's disease is a matter of updating government policy to match the current science. (Robert R. Redfield, 11/14)

Uniqure CEO Matt Kapusta told a group of investors at a private dinner on Tuesday that the Trump White House “doesn’t like all the drama” inside the Food and Drug Administration, just a week after the company said the agency had upended its plan to seek a speedy approval for a gene therapy to treat Huntington’s disease. (Adam Feuerstein, 11/13)